Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Successful results in developing oral vaccin against diarrhea

22.05.2013
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of diarrhea in children living in low and middle income countries result in 400 million diarrheal episodes and approximately 300 000 deaths among children per year.

ETEC is also the leading cause of illness among international travelers to developing countries. Among the 65 million people travelling from industrialized countries to ETEC high-risk areas in the developing world, 30-50 % (ca 30 million people) experience at least one TD episode during their journey. Today there is no ETEC vaccine available on the market for use in either children or travelers in ETEC high-risk areas.

A novel oral ETEC vaccine has been developed in Sweden and a clinical phase I-study of this vaccine has now been successfully completed. All predefined primary endpoints for the study were achieved showing that the vaccine is safe, with only few and mild adverse reactions observed, and strongly immunogenic, stimulating immune responses to all vaccine components.

The vaccine, consisting of four inactivated E. coli bacterial strains and the ETEC-based B subunit protein LCTBA, was studied for safety and immunogenicity in a total of 129 healthy volunteers. The study was designed as a four-armed, double-blinded, placebo-controlled trial. Study participants were randomized to receive two oral doses two weeks apart of either the vaccine alone, vaccine co-administered with an oral adjuvant in a low or a higher dose, or an inactive placebo preparation (a buffer solution).

In addition to safety parameters, antibody responses against various vaccine components in fecal samples, or antibodies produced by intestine-derived peripheral blood lymphocytes were measured at different time intervals.

The vaccine was well tolerated by the study participants. Adverse events were few and generally mild with no difference observed in subjects receiving vaccine or a placebo preparation. In total, 75% of all vaccine recipients responded to all 5 of the primary vaccine components, a result that well exceeds the primary immunological endpoint for the study (at least 50 percent of the subjects responding to at least 4 of the primary vaccine antigens).

Furthermore, 85 % of subjects receiving the vaccine co-administered with low dose adjuvant showed significant immune responses to all vaccine components. In addition to showing excellent safety and immunogenicity of the five-component vaccine, the results also confirm previous preclinical results as well as clinical results obtained with a prototype version of this vaccine.

This study was conducted at the Sahlgrenska Academy of University of Gothenburg as a collaborative effort between University of Gothenburg Vaccine Research Institute, Scandinavian Biopharma, Stockholm and the non-profit organization PATH, Washington D.C. The results will be presented at the Mucosal Vaccines, Adjuvants and Delivery Conference in Copenhagen, September 25-27 2013 and the 7th International Conference on Vaccines for Enteric Diseases, 6-8 November 2013 in Bangkok, Thailand.

Based on these very encouraging results, additional clinical studies are planned to document protective efficacy in travelers, and to study the safety and immunogenicity of the vaccine when given to children living in areas endemic for ETEC.

For more information, please contact:
Ann-Mari Svennerholm
+ 46 (0)317866202;
+46708 298 960,
ann-mari.svennerholm@microbio.gu.se (GUVAX)

Anna Lundgren
+46 (0)317866213;
anna.lundgren@microbio.gu.se (GUVAX)

Jan Holmgren
+46 (0)317866201;
jan.holmgren@microbio.gu.se (GUVAX)

Annika Koldenius | idw
Further information:
http://www.gu.se

Further reports about: ETEC Escherichia coli GUVAX high-risk areas immune response

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>